133:
flow. Patients with extrahepatic metastatic disease are also not candidates for resection, and therefore PVE is contraindicated. In the past patients with bi-lobar disease were not considered for PVE, however now there may be a role of PVE in combination with a two-stage hepatectomy. Additionally, patients who have an inadequate predicted FLR post PVE should not be considered. Other contraindications include any conditions that make a patient unfit for surgery or intervention (poor cardiopulmonary status,
209:. This means that it is an increase in the number of hepatocytes that accounts for the growth rather than the increase in size of existing hepatocytes. The liver is unique in that it is an organ with regenerative potential. When blood flow to one section of the liver is occluded in PVE, the flow is diverted to other areas and this increase in blood flow stimulates the regenerative response. Regeneration begins within hours of occlusion and factors important to this response include
286:
sponge dissolved in a 4:1 mixture of iodinated contrast medium and saline has been used and shown induce FLR hypertrophy. However, whether it can provide the comparable response to traditional PVE must still be studied. In the future, reversible PVE may also play a role in treating patients with chronic hepatic insufficiency to increase functional liver tissue, as opposed to just being used as an adjuvant therapy for liver resection.
104:
patients with otherwise normal livers. The recommendation for those with chronic liver disease such as cirrhosis is a FLR/TELV ratio of at least 40%. In these patients a PVE may be indicated to increase the FLR and the FLR/TELV ratio. Preoperative patients receiving extensive chemotherapy with a FLR/TELV less than 30% should also receive PVE prior to resection; conversely, chemotherapy does not preclude subsequent PVE.
117:
and other risks as listed above. Success of PVE is determined by degree of regenerative response, which again depends on factors such as baseline liver condition, technical approach and pre-existing co-morbidities. Five-year survival in patients with originally unresectable tumors as a result of inadequate future liver remnant and received PVE with subsequent resection was found in one study to be 29%.
277:
percutaneous PVE were found to be nearly double. No significant adverse events were noted. The advantage to this new approach is a better safety profile (does not require direct hepatic puncture). However, this approach may be limited by the amount of embolic agent needed for successful embolization, as the amount needed for humans may exceed the threshold for pulmonary complications.
229:, among others. The expected increase in FLR is approximately 10 percent; greater increases after four to six weeks can be observed, albeit at a lower rate of growth. An increase in FLR of greater than five percent for a normal liver and 10 percent for a cirrhotic liver is considered adequate and is associated with a reduced risk of post-resection liver failure.
294:
Studies have shown that bone marrow-derived stem cells (specifically CD133+) play a role in liver regeneration. A study done by Esch, et al. showed that patients who received stem cells in addition to PVE had significant increases in both absolute and relative FLR growth than in patients who received
120:
Originally, there was concern that PVE could promote tumor growth and increase recurrence rates, however a systematic review has found that there was no significant difference observed in postoperative hepatic recurrence or 3 and 5 year overall survival rates. This suggests that PVE does not have any
103:
Indications for PVE depend on the ratio of future liver remnant (FLR) to total estimated liver volume (TELV) and liver condition. Although there is no consensus to the absolute minimum liver volume required for adequate post-resection liver function, a FLR/TELV ratio of at least 25% is recommended in
251:
To determinate whether there is a need for PVE the FLR needs to be measured. There are various imaging methods used in order to measure the liver volume such as contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) and the FLR can be traced either manually or using automatic
132:
is an absolute contraindication, as these patients are not surgical candidates and are at higher risk of significant complications from PVE. Additionally, complete lobar portal vein occlusion of either lobe would preclude expected increases in FLR from PVE due to already existing diversion of portal
116:
Preoperative PVE is a very well tolerated procedure with extremely low mortality rates (0.1 percent) and technical failure rates (0.4 percent). Complication rates from the procedure are low as well (2–3 percent) and include portal vein thrombosis, liver infarction, necrosis, infection, pneumothorax,
285:
There are times when a patient who has undergone a PVE is no longer able to undergo a resection. In these instances, the patients are left with a permanently occluded portal vein that can exclude them from receiving other therapies. Therefore, PVE with absorbable materials such as powdered gelatin
242:
can be used and the choice of agents often depend on the expertise of the physician, availability and cost. As the agents differ in size, occlusive properties and side effect profiles, the choice of agent will also depend on the anatomy and locations of the tumors in a specific case. Some commonly
107:
Other important considerations before a PVE include co-morbidities such as diabetes, procedure type and the extent of planned resection. Insulin resistance has been associated with slower rates of regeneration and higher likelihood of inadequate FLR growth after PVE. Additionally, if the resection
534:
Giglio, Mariano Cesare; Giakoustidis, Alexandros; Draz, Ahmed; Jawad, Zaynab A. R.; Pai, Madhava; Habib, Nagy A.; Tait, Paul; Frampton, Adam E.; Jiao, Long R. (2016-10-01). "Oncological
Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis".
197:
to initiate hypertrophy of the anticipated future liver remnant a couple weeks prior to a major liver resection procedure. Future liver remnant (FLR) is defined as the predicted volume of functional liver after resection. There are specific FLR thresholds depending on the status of the liver
237:
PVE was originally performed using an open approach, but the majority is now done percutaneously under conscious sedation and local anesthesia by an interventional radiologist. This can be done using either a transjugular or transhepatic approach. The most commonly used method is the direct
276:
A technique tested so far in pigs in which a 3:1 mixture of iodinated oil and absolute ethanol was infused via lobar hepatic artery branches and into the portal system via the peribiliary plexus. The degree of FLR hypertrophy seen in the pigs with transarterial PVE compared to traditional
198:(otherwise normal, chronic hepatitis, cirrhosis, etc.) that are required for safe liver resection. When the predicted FLR is below threshold, portal vein embolization may increase the FLR and bring it to threshold. The majority of preoperative PVEs usually target the right
82:
procedure. The procedure involves injecting the right or left portal vein with embolic material to occlude portal blood flow. By occluding the blood flow to areas of the liver that will be resected away, the blood is diverted to healthy parts of the liver and induces
121:
significant adverse effects on the risk of oncogenesis. Overall, PVE is an important technique that can allow for patients with inadequate predicted FLR/TELV ratios an opportunity for resection and potential cure of their liver conditions.
295:
PVE only. They found no significant differences between the groups in regards to major complications and mortality. This suggests that adjuvant stem cell transplantation can increase the efficacy of PVE without increasing risk.
648:
Denys, A. L.; Abehsera, M.; Leloutre, B.; Sauvanet, A.; Vilgrain, V.; O'Toole, D.; Belghiti, J.; Menu, Y. (2000-10-01). "Intrahepatic hemodynamic changes following portal vein embolization: a prospective
Doppler study".
893:
am Esch, Jan
Schulte; Knoefel, Wolfram Trudo; Klein, Michael; Ghodsizad, Ali; Fuerst, Guenter; Poll, Ludger W.; Piechaczek, Christoph; Burchardt, Elmar R.; Feifel, Niko (2005-04-01).
376:
Loffroy, Romaric; Favelier, Sylvain; Chevallier, Olivier; Estivalet, Louis; Genson, Pierre-Yves; Pottecher, Pierre; Gehin, Sophie; Krausé, Denis; Cercueil, Jean-Pierre (2015-10-15).
703:
May, Benjamin J.; Talenfeld, Adam D.; Madoff, David C. (February 2013). "Update on Portal Vein
Embolization: Evidence-based Outcomes, Controversies, and Novel Strategies".
252:
or semi-automatic segmentation tools. FLR is measured with the chosen imaging method before PVE and then again 1–4 weeks after PVE calculating the hypertrophy of the FLR.
596:
Madoff, David C.; Hicks, Marshall E.; Vauthey, Jean-Nicolas; Charnsangavej, Chusilp; Morello, Frank A.; Ahrar, Kamran; Wallace, Michael J.; Gupta, Sanjay (2002-09-01).
795:
Imamura, Hiroshi; Shimada, Ryo; Kubota, Mitsuru; Matsuyama, Yutaka; Nakayama, Ataru; Miyagawa, Shin-ichi; Makuuchi, Masatoshi; Kawasaki, Seiji (1999-04-01).
184:
Poor regenerative response to PVE predicts poor compensatory regeneration following liver resection and can help identify patients unsuitable for resection.
108:
requires more extensive surgery such as a resections of the pancreas or small bowel, a greater FLR/TELV ratio may be needed for safe recovery.
428:
Lienden, K. P. van; Esschert, J. W. van den; Graaf, W. de; Bipat, S.; Lameris, J. S.; Gulik, T. M. van; Delden, O. M. van (2013-02-01).
243:
used agents include cyanoacrylate, sodium tetradecyl sulfate foam, gelatin, metallic spherical particles, coils and absolute alcohol.
202:
in preparation of a major right-sided resection. Though rare, the left portal vein may be embolized prior to a left-sided resection.
159:
Accelerated tumor growth due to compensatory hepatic arterial flow and in cases when all of the tumor-bearing areas are not properly
947:
316:
Abdalla, E. K.; Hicks, M. E.; Vauthey, J. N. (2001-02-01). "Portal vein embolization: rationale, technique and future prospects".
895:"Portal Application of Autologous CD133+ Bone Marrow Cells to the Liver: A Novel Concept to Support Hepatic Regeneration"
226:
487:"Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization"
210:
194:
75:
740:"Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome"
214:
222:
31:
87:. This may allow for a more extensive resection or stage bilateral resections that would otherwise be
738:
Ribero, D.; Abdalla, E. K.; Madoff, D. C.; Donadon, M.; Loyer, E. M.; Vauthey, J.-N. (2007-11-01).
174:
Patients initially with unresectable tumors due to inadequate FLR/TELV are able to have resections.
171:
Decrease post-resection morbidity by decreasing number of complication and length of hospital stay.
129:
777:
682:
578:
349:
239:
78:
to initiate hypertrophy of the anticipated future liver remnant a couple weeks prior to a major
952:
924:
916:
875:
826:
818:
769:
761:
720:
674:
666:
627:
619:
570:
562:
516:
467:
449:
407:
341:
333:
45:
378:"Preoperative portal vein embolization in liver cancer: indications, techniques and outcomes"
906:
865:
857:
808:
751:
712:
658:
609:
552:
544:
506:
498:
457:
441:
397:
389:
325:
614:
598:"Transhepatic Portal Vein Embolization: Anatomy, Indications, and Technical Considerations"
597:
88:
156:
Risks related to any percutaneous transhepatic procedures such as bleeding and infection.
393:
17:
870:
845:
511:
486:
462:
429:
402:
377:
138:
941:
502:
329:
781:
686:
582:
353:
911:
894:
206:
199:
92:
84:
79:
716:
177:
Decrease post-resection mortality by increasing the volume of functional liver
548:
445:
178:
920:
822:
765:
670:
623:
566:
453:
337:
160:
928:
879:
861:
830:
773:
724:
678:
631:
574:
557:
520:
471:
411:
345:
153:
Portal vein thrombosis, liver infarction, necrosis and portal hypertension.
813:
796:
662:
57:
205:
The increase in FLR is a result of cellular hyperplasia and not cellular
218:
430:"Portal Vein Embolization Before Liver Resection: A Systematic Review"
756:
739:
134:
193:
Portal vein embolization is a preoperative procedure performed in
797:"Preoperative portal vein embolization: An audit of 84 patients"
238:
transhepatic puncture of the portal vein. Several different
846:"Standardized liver volumetry for portal vein embolization"
30:
Do not confuse portal vein embolization (a procedure) with
167:PVE has been shown to have the following benefits:
44:
39:
705:Journal of Vascular and Interventional Radiology
149:PVE has been shown to have the following risks:
844:Ribero, D; Chun, YS; Vauthey, JN (June 2008).
8:
382:Quantitative Imaging in Medicine and Surgery
434:CardioVascular and Interventional Radiology
290:PVE with adjuvant stem cell transplantation
74:) is a preoperative procedure performed in
910:
869:
812:
755:
613:
556:
510:
461:
401:
303:
615:10.1148/radiographics.22.5.g02se161063
36:
7:
850:Seminars in Interventional Radiology
698:
696:
643:
641:
423:
421:
371:
369:
367:
365:
363:
311:
309:
307:
394:10.3978/j.issn.2223-4292.2015.10.04
53:
25:
503:10.1097/00000658-200004000-00005
485:Azoulay, D; et al. (2000).
330:10.1046/j.1365-2168.2001.01658.x
1:
912:10.1634/stemcells.2004-0283
537:Annals of Surgical Oncology
969:
744:British Journal of Surgery
717:10.1016/j.jvir.2012.10.017
318:British Journal of Surgery
29:
549:10.1245/s10434-016-5264-6
446:10.1007/s00270-012-0440-y
54:
948:Interventional radiology
211:hepatocyte growth factor
195:interventional radiology
76:interventional radiology
68:Portal vein embolization
50:Interventional radiology
40:Portal vein embolization
18:Portal Vein Embolization
215:epidermal growth factor
862:10.1055/s-2008-1076681
32:portal vein thrombosis
27:Preoperative procedure
814:10.1002/hep.510290415
663:10.1007/s003300000577
95:treatment outcomes.
91:resulting in better
240:embolization agents
130:Portal hypertension
651:European Radiology
145:Risks and Benefits
750:(11): 1386–1394.
657:(11): 1703–1707.
543:(11): 3709–3717.
272:Transarterial PVE
256:Future directions
125:Contraindications
65:
64:
16:(Redirected from
960:
933:
932:
914:
890:
884:
883:
873:
841:
835:
834:
816:
807:(4): 1099–1105.
792:
786:
785:
759:
757:10.1002/bjs.5836
735:
729:
728:
700:
691:
690:
645:
636:
635:
617:
608:(5): 1063–1076.
593:
587:
586:
560:
531:
525:
524:
514:
482:
476:
475:
465:
425:
416:
415:
405:
373:
358:
357:
313:
268:
267:
263:
58:edit on Wikidata
37:
21:
968:
967:
963:
962:
961:
959:
958:
957:
938:
937:
936:
892:
891:
887:
843:
842:
838:
794:
793:
789:
737:
736:
732:
702:
701:
694:
647:
646:
639:
595:
594:
590:
533:
532:
528:
484:
483:
479:
427:
426:
419:
375:
374:
361:
315:
314:
305:
301:
292:
283:
274:
269:
265:
261:
259:
258:
249:
247:Liver volumetry
235:
191:
147:
127:
114:
101:
89:contraindicated
80:liver resection
61:
35:
28:
23:
22:
15:
12:
11:
5:
966:
964:
956:
955:
950:
940:
939:
935:
934:
905:(4): 463–470.
885:
836:
787:
730:
711:(2): 241–254.
692:
637:
588:
526:
497:(4): 480–486.
477:
417:
388:(5): 730–739.
359:
324:(2): 165–175.
302:
300:
297:
291:
288:
282:
281:Reversible PVE
279:
273:
270:
257:
254:
248:
245:
234:
231:
190:
187:
186:
185:
182:
175:
172:
165:
164:
157:
154:
146:
143:
139:kidney failure
126:
123:
113:
110:
100:
97:
63:
62:
55:
52:
51:
48:
42:
41:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
965:
954:
951:
949:
946:
945:
943:
930:
926:
922:
918:
913:
908:
904:
900:
896:
889:
886:
881:
877:
872:
867:
863:
859:
855:
851:
847:
840:
837:
832:
828:
824:
820:
815:
810:
806:
802:
798:
791:
788:
783:
779:
775:
771:
767:
763:
758:
753:
749:
745:
741:
734:
731:
726:
722:
718:
714:
710:
706:
699:
697:
693:
688:
684:
680:
676:
672:
668:
664:
660:
656:
652:
644:
642:
638:
633:
629:
625:
621:
616:
611:
607:
603:
602:RadioGraphics
599:
592:
589:
584:
580:
576:
572:
568:
564:
559:
558:10044/1/31671
554:
550:
546:
542:
538:
530:
527:
522:
518:
513:
508:
504:
500:
496:
492:
488:
481:
478:
473:
469:
464:
459:
455:
451:
447:
443:
439:
435:
431:
424:
422:
418:
413:
409:
404:
399:
395:
391:
387:
383:
379:
372:
370:
368:
366:
364:
360:
355:
351:
347:
343:
339:
335:
331:
327:
323:
319:
312:
310:
308:
304:
298:
296:
289:
287:
280:
278:
271:
264:
255:
253:
246:
244:
241:
232:
230:
228:
224:
220:
216:
212:
208:
203:
201:
196:
188:
183:
180:
176:
173:
170:
169:
168:
162:
158:
155:
152:
151:
150:
144:
142:
140:
136:
131:
124:
122:
118:
111:
109:
105:
98:
96:
94:
90:
86:
81:
77:
73:
69:
59:
49:
47:
43:
38:
34:(a disorder).
33:
19:
902:
898:
888:
856:(2): 104–9.
853:
849:
839:
804:
800:
790:
747:
743:
733:
708:
704:
654:
650:
605:
601:
591:
540:
536:
529:
494:
490:
480:
440:(1): 25–34.
437:
433:
385:
381:
321:
317:
293:
284:
275:
250:
236:
204:
192:
166:
148:
128:
119:
115:
106:
102:
99:Medical uses
71:
67:
66:
207:hypertrophy
200:portal vein
93:oncological
85:hyperplasia
942:Categories
899:Stem Cells
801:Hepatology
299:References
179:parenchyma
921:1549-4918
823:1527-3350
766:1365-2168
671:0938-7994
624:0271-5333
567:1068-9265
454:0174-1551
338:1365-2168
227:TNF-alpha
189:Mechanism
161:embolized
141:, etc.).
46:Specialty
953:Oncology
929:15790766
880:21326551
831:10094953
782:38615358
774:17583900
725:23369559
687:23986141
679:11097391
632:12235336
583:22655871
575:27272106
521:10749607
491:Ann Surg
472:22806245
412:26682142
354:22645135
346:11167863
112:Outcomes
871:3036478
512:1421022
463:3549243
403:4671969
219:insulin
927:
919:
878:
868:
829:
821:
780:
772:
764:
723:
685:
677:
669:
630:
622:
581:
573:
565:
519:
509:
470:
460:
452:
410:
400:
352:
344:
336:
260:": -->
233:Method
135:sepsis
778:S2CID
683:S2CID
579:S2CID
350:S2CID
56:[
925:PMID
917:ISSN
876:PMID
827:PMID
819:ISSN
770:PMID
762:ISSN
721:PMID
675:PMID
667:ISSN
628:PMID
620:ISSN
571:PMID
563:ISSN
517:PMID
468:PMID
450:ISSN
408:PMID
342:PMID
334:ISSN
262:edit
225:and
223:IL-6
907:doi
866:PMC
858:doi
809:doi
752:doi
713:doi
659:doi
610:doi
553:hdl
545:doi
507:PMC
499:doi
495:231
458:PMC
442:doi
398:PMC
390:doi
326:doi
72:PVE
944::
923:.
915:.
903:23
901:.
897:.
874:.
864:.
854:25
852:.
848:.
825:.
817:.
805:29
803:.
799:.
776:.
768:.
760:.
748:94
746:.
742:.
719:.
709:24
707:.
695:^
681:.
673:.
665:.
655:10
653:.
640:^
626:.
618:.
606:22
604:.
600:.
577:.
569:.
561:.
551:.
541:23
539:.
515:.
505:.
493:.
489:.
466:.
456:.
448:.
438:36
436:.
432:.
420:^
406:.
396:.
384:.
380:.
362:^
348:.
340:.
332:.
322:88
320:.
306:^
221:,
217:,
213:,
137:,
931:.
909::
882:.
860::
833:.
811::
784:.
754::
727:.
715::
689:.
661::
634:.
612::
585:.
555::
547::
523:.
501::
474:.
444::
414:.
392::
386:5
356:.
328::
266:]
181:.
163:.
70:(
60:]
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.